Patents by Inventor Richard J. Rickles

Richard J. Rickles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
    Publication number: 20220280495
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: September 9, 2021
    Publication date: September 8, 2022
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
    Patent number: 10881648
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 5, 2021
    Assignee: AMGEN INC.
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
    Publication number: 20190290630
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 26, 2019
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
    Publication number: 20160287569
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: November 11, 2014
    Publication date: October 6, 2016
    Applicant: AMGEN INC.
    Inventors: Sean CAENEPEEL, Jude CANON, Paul HUGHES, Jonathan D. OLINER, Anne Y. SAIKI, Richard J. RICKLES
  • Cell based assay for identifying sh2-domain-specific signal transducer antagonist
    Patent number: 6303319
    Abstract: The present invention provides methods and compositions for identifying inhibitors of the interaction between phosphopeptide binding pairs, i.e., a protein domain having at least one phosphopeptide binding domain and the phosphorylated ligands that bind these domains. These inhibitors may be used for pharmaceutical compositions and in therapeutic treatments for diseases in which a phosphopeptide domain binding is implicated.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: October 16, 2001
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventor: Richard J. Rickles